Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer

Sikander Ailawadhi, Annette Sunga, Ashwani Rajput, Gary Y. Yang, Judy Smith, Marwan Fakih

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives: To investigate the incidence of carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer (MCRC) and its implications on clinical outcome. Methods: A retrospective chart review of patients with MCRC treated with chemotherapy at Roswell Park Cancer Institute from January 2000 to May 2004 was conducted. A CEA surge was defined as an increase of >20% from baseline followed by a >20% drop in one or more subsequent CEA levels compared to baseline. The incidence of CEA surge and its association with clinical outcome was investigated. Results: Eighty-nine patients were evaluable for CEA surge. A CEA surge was documented in 10 patients. The CEA surge lasted <4 months in all 10 patients and was associated with a clinical benefit. No significant correlation was noted between CEA surge and site of primary tumor, site of metastatic disease, or tumor differentiation. Conclusions: CEA surges can be observed in patients receiving chemotherapy for MCRC and are often associated with a clinical benefit. None of the CEA surges satisfied the American Society of Clinical Oncology definition of CEA progression. A rise in CEA after initiation of chemotherapy, unless lasting >4 months, cannot be used as an indicator of progressive disease.

Original languageEnglish (US)
Pages (from-to)49-53
Number of pages5
JournalOncology
Volume70
Issue number1
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
Colorectal Neoplasms
Drug Therapy
Incidence
Neoplasms

Keywords

  • Carcinoembryonic antigen
  • CEA surge
  • Chemotherapy
  • FOLFOX
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. / Ailawadhi, Sikander; Sunga, Annette; Rajput, Ashwani; Yang, Gary Y.; Smith, Judy; Fakih, Marwan.

In: Oncology, Vol. 70, No. 1, 03.2006, p. 49-53.

Research output: Contribution to journalArticle

Ailawadhi, Sikander ; Sunga, Annette ; Rajput, Ashwani ; Yang, Gary Y. ; Smith, Judy ; Fakih, Marwan. / Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. In: Oncology. 2006 ; Vol. 70, No. 1. pp. 49-53.
@article{7c615826754c46e1bbaac57be49b7dc0,
title = "Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer",
abstract = "Objectives: To investigate the incidence of carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer (MCRC) and its implications on clinical outcome. Methods: A retrospective chart review of patients with MCRC treated with chemotherapy at Roswell Park Cancer Institute from January 2000 to May 2004 was conducted. A CEA surge was defined as an increase of >20{\%} from baseline followed by a >20{\%} drop in one or more subsequent CEA levels compared to baseline. The incidence of CEA surge and its association with clinical outcome was investigated. Results: Eighty-nine patients were evaluable for CEA surge. A CEA surge was documented in 10 patients. The CEA surge lasted <4 months in all 10 patients and was associated with a clinical benefit. No significant correlation was noted between CEA surge and site of primary tumor, site of metastatic disease, or tumor differentiation. Conclusions: CEA surges can be observed in patients receiving chemotherapy for MCRC and are often associated with a clinical benefit. None of the CEA surges satisfied the American Society of Clinical Oncology definition of CEA progression. A rise in CEA after initiation of chemotherapy, unless lasting >4 months, cannot be used as an indicator of progressive disease.",
keywords = "Carcinoembryonic antigen, CEA surge, Chemotherapy, FOLFOX, Metastatic colorectal cancer",
author = "Sikander Ailawadhi and Annette Sunga and Ashwani Rajput and Yang, {Gary Y.} and Judy Smith and Marwan Fakih",
year = "2006",
month = "3",
doi = "10.1159/000091184",
language = "English (US)",
volume = "70",
pages = "49--53",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer

AU - Ailawadhi, Sikander

AU - Sunga, Annette

AU - Rajput, Ashwani

AU - Yang, Gary Y.

AU - Smith, Judy

AU - Fakih, Marwan

PY - 2006/3

Y1 - 2006/3

N2 - Objectives: To investigate the incidence of carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer (MCRC) and its implications on clinical outcome. Methods: A retrospective chart review of patients with MCRC treated with chemotherapy at Roswell Park Cancer Institute from January 2000 to May 2004 was conducted. A CEA surge was defined as an increase of >20% from baseline followed by a >20% drop in one or more subsequent CEA levels compared to baseline. The incidence of CEA surge and its association with clinical outcome was investigated. Results: Eighty-nine patients were evaluable for CEA surge. A CEA surge was documented in 10 patients. The CEA surge lasted <4 months in all 10 patients and was associated with a clinical benefit. No significant correlation was noted between CEA surge and site of primary tumor, site of metastatic disease, or tumor differentiation. Conclusions: CEA surges can be observed in patients receiving chemotherapy for MCRC and are often associated with a clinical benefit. None of the CEA surges satisfied the American Society of Clinical Oncology definition of CEA progression. A rise in CEA after initiation of chemotherapy, unless lasting >4 months, cannot be used as an indicator of progressive disease.

AB - Objectives: To investigate the incidence of carcinoembryonic antigen (CEA) surge in patients with metastatic colorectal cancer (MCRC) and its implications on clinical outcome. Methods: A retrospective chart review of patients with MCRC treated with chemotherapy at Roswell Park Cancer Institute from January 2000 to May 2004 was conducted. A CEA surge was defined as an increase of >20% from baseline followed by a >20% drop in one or more subsequent CEA levels compared to baseline. The incidence of CEA surge and its association with clinical outcome was investigated. Results: Eighty-nine patients were evaluable for CEA surge. A CEA surge was documented in 10 patients. The CEA surge lasted <4 months in all 10 patients and was associated with a clinical benefit. No significant correlation was noted between CEA surge and site of primary tumor, site of metastatic disease, or tumor differentiation. Conclusions: CEA surges can be observed in patients receiving chemotherapy for MCRC and are often associated with a clinical benefit. None of the CEA surges satisfied the American Society of Clinical Oncology definition of CEA progression. A rise in CEA after initiation of chemotherapy, unless lasting >4 months, cannot be used as an indicator of progressive disease.

KW - Carcinoembryonic antigen

KW - CEA surge

KW - Chemotherapy

KW - FOLFOX

KW - Metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=33644918872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644918872&partnerID=8YFLogxK

U2 - 10.1159/000091184

DO - 10.1159/000091184

M3 - Article

C2 - 16446549

AN - SCOPUS:33644918872

VL - 70

SP - 49

EP - 53

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -